180 filings
8-K
AGRX
Agile Therapeutics Inc
9 Apr 24
Results of Operations and Financial Condition
8:30am
8-K
AGRX
Agile Therapeutics Inc
28 Mar 24
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
9:06am
8-K
AGRX
Agile Therapeutics Inc
25 Mar 24
Agile Therapeutics Announces Delisting from Nasdaq
4:30pm
8-K
AGRX
Agile Therapeutics Inc
14 Mar 24
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
4:45pm
8-K
AGRX
Agile Therapeutics Inc
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
1yi0ym
15 Feb 24
Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022
4:45pm
8-K
du3eg 8ec5x
6 Dec 23
Other Events
8:00am
8-K
3piw2hitz ydx4b
4 Dec 23
Entry into a Material Definitive Agreement
8:00am
8-K
53a2yweti f0c0t
9 Nov 23
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
8:15am
8-K
629wal08v qx
2 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
ae8m0w
28 Sep 23
Entry into a Material Definitive Agreement
4:50pm
8-K/A
ca5b0wbqm8x
22 Aug 23
Departure of Directors or Certain Officers
8:30am
8-K
qbahbh 1cxc2e
9 Aug 23
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8:10am
8-K
532ccnvf4hr
30 Jun 23
Departure of Directors or Certain Officers
4:50pm
8-K
90aqvryoei76bm
27 Jun 23
Departure of Directors or Certain Officers
4:46pm
8-K/A
pdpsx9ch
14 Jun 23
Departure of Directors or Certain Officers
4:35pm
8-K
tukmjy
8 Jun 23
Submission of Matters to a Vote of Security Holders
4:35pm
8-K
fzyweeadfu10ukdlenl
5 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
8-K
iuq6po
25 May 23
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
5:25pm
8-K
qr4hmf62ba7kmsb0shma
17 May 23
Other Events
7:30am